Safety and efficacy of daptomycin for the treatment of hospitalized adult patients in Taiwan with severe staphylococcal infections

Journal of Microbiology, Immunology and Infection

Volumn 45, Issue 1, 2012, Pages 52-57

  Lai, Chung Chih ^a   Sheng, Wang Huei ^a   Wang, Jann Tay ^a   Liao, Chun Hsin ^b   Ho, Mao Wang ^c   Chen, Chwen Je ^d   Chen, Der Li ^e   Chou, Ming Uen ^f   Lee, Chien Ming ^g   Lin, Yee Chun ^h   Pong, Ming Ye ⁱ   Chang, Shan Chwen ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^f Jeng Shin Medical Center   (Taiwan)

^g CHI MEI MEDICAL CENTER   (Taiwan)

^h TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

ⁱ TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Daptomycin; Methicillin resistant Staphylococcus aureus; Serious infection

Indexed keywords

AMINOTRANSFERASE; CREATINE KINASE; CREATININE; DAPTOMYCIN; FUSIDIC ACID; GENTAMICIN; LINEZOLID; POLYPEPTIDE ANTIBIOTIC AGENT; RIFAMPICIN; TEICOPLANIN; VANCOMYCIN;

ACINETOBACTER INFECTION; ADULT; AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIAL ARTHRITIS; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; BROTH DILUTION; CANDIDEMIA; CATHETER INFECTION; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CHRONIC HEPATITIS; CHRONIC LUNG DISEASE; CLINICAL EXAMINATION; COMORBIDITY; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DEATH; DIABETES MELLITUS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ENDOCARDITIS; ENDOVASCULAR INFECTION; ESCHERICHIA COLI INFECTION; FEMALE; FOLLOW UP; GRAFT SEPTIC THROMBOPHLEBITIS; HEMODIALYSIS PATIENT; HOSPITAL PATIENT; HOSPITAL READMISSION; HUMAN; INFECTION; KIDNEY FAILURE; KLEBSIELLA PNEUMONIAE INFECTION; LEUKOPENIA; LIVER CIRRHOSIS; LUNG ABSCESS; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MICROBIOLOGICAL EXAMINATION; MINIMUM INHIBITORY CONCENTRATION; MIXED INFECTION; MULTIPLE ORGAN FAILURE; MYALGIA; MYCOSIS; MYCOTIC AORTIC ANEURYSM; OSTEOMYELITIS; OUTCOME ASSESSMENT; PERSISTENT INFECTION; PROSTHESIS INFECTION; PRURITUS; PSEUDOMONAS INFECTION; SEPTIC SHOCK; SIDE EFFECT; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS INFECTION; TAIWAN; THROMBOPHLEBITIS; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; UREMIA; URINARY TRACT INFECTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; DAPTOMYCIN; FEMALE; HOSPITALIZATION; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; TAIWAN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84856287557     PISSN: 16841182     EISSN: 19959133     Source Type: Journal    
DOI: 10.1016/j.jmii.2011.09.018     Document Type: Article

References (36)

1. National nosocomial infections surveillance (NNIS) system report Data summary from January 1992 through June 2004. Am J Infect Control 2004, 32:470-485.
2. González C., Rubio M., Romero-Vivas J., González M., Picazo J.J. Bacteremic pneumonia due to Staphylococcus aureus: a comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis 1999, 29:1171-1177.
3. Fowler V.G., Kong L.K., Corey G.R., Gottlieb G.S., McClelland R.S., Sexton D.J., et al. Recurrent Staphylococcus aureus bacteremia: pulsed-field gel electrophoresis findings in 29 patients. J Infect Dis 1999, 179:1157-1161.
4. Sakoulas G., Moise-Broder P.A., Schentag J., Forrest A., Moellering R.C., Eliopoulos G.M. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004, 42:2398-2402.
5. Thorne G.M. Daptomycin: a novel lipopeptide antibiotic. Clin Microbiol News 2002, 24:33-40.
6. Cubist Pharmaceuticals Cubicin (daptomycin for injection) product information 2003, Cubist Pharmaceuticals, Lexington, MA.
7. Arbeit R.D., Maki D., Tally F.P., Campanaro E., Eisenstein B.I. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004, 38:1673-1681.
8. Fowler V.G., Boucher H.W., Corey G.R., Abrutyn E., Karchmer A.W., Rupp M.E., et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006, 355:653-665.
9. Rehm S.J., Boucher H., Levine D., Campion M., Eisenstein B.I., Vigliani G.A., et al. Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates. J Antimicrob Chemother 2008, 62:1413-1421.
10. Crompton J.A., North D.S., McConnell S.A., Lamp K.C. Safety and efficacy of daptomycin in the treatment of osteomyelitis: results from the CORE registry. J Chemother 2009, 21:414-420.
11. Moise P.A., Hershberger E., Amodio-Groton M.I., Lamp K.C. Safety and clinical outcomes when utilizing high-dose (> or =8mg/kg) daptomycin therapy. Ann Pharmacother 2009, 43:1211-1219.
12. Chamberlain R.S., Culshaw D.L., Donovan B.J., Lamp K.C. Daptomycin for the treatment of surgical site infections. Surgery 2009, 146:316-324.
13. Figueroa D.A., Mangini E., Amodio-Groton M., Vardianos B., Melchert A., Fana C., et al. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis 2009, 49:177-180.
14. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A7, 7th ed. Wayne, PA: CLSI 2009.
15. Fuchs P.C., Barry A.L., Brown S.D. Daptomycin susceptibility tests: interpretive criteria, quality control, and effect of calcium on invitro tests. Diagn Microbiol Infect Dis 2000, 38:51-58.
16. Smith T.L., Pearson M.L., Wilcox K.R., Cruz C., Lancaster M.V., Robinson-Dunn B., et al. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 1999, 340:493-501.
17. Nishimura S., Tsurumoto T., Yonekura A., Adachi K., Shindo H. Antimicrobial susceptibility of Staphylococcus aureus and Staphylococcus epidermidis biofilms isolated from infected total hip arthroplasty cases. J Orthop Sci 2006, 11:46-50.
18. Weigel L.M., Donlan R.M., Shin D.H., Jensen B., Clark N.C., McDougal L.K., et al. High-level vancomycin-resistant Staphylococcus aureus isolates associated with a polymicrobial biofilm. Antimicrob Agents Chemother 2007, 51:231-238.
19. Woodworth J.R., Nyhart E.H., Brier G.L., Wolny J.D., Black H.R. Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers. Antimicrob Agents Chemother 1992, 36:318-325.
20. Rybak M.J., Hershberger E., Moldovan T., Grucz R.G. Invitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob Agents Chemother 2000, 44:1062-1066.
21. Rose W.E., Leonard S.N., Rybak M.J. Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an invitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2008, 52:3061-3067.
22. Tally F.P., DeBruin M.F. Development of daptomycin for Gram-positive infections. J Antimicrob Chemother 2000, 46:523-526.
23. Segreti J.A., Crank C.W., Finney M.S. Daptomycin for the treatment of Gram-positive bacteremia and infective endocarditis: a retrospective case series of 31 patients. Pharmacotherapy 2006, 26:347-352.
24. Vikram H.R., Havill N.L., Koeth L.M., Boyce J.M. Clinical progression of methicillin resistant Staphylococcus aureus vertebral osteomyelitis associated with reduced susceptibility to daptomycin. J Clin Microbiol 2005, 43:5384-5387.
25. Marty F.M., Yeh W.W., Wennersten C.B., Venkataraman L., Albano E., Alyea E.P., et al. Emergence of a clinical daptomycin resistant Staphylococcus aureus isolate during treatment of methicillin resistant Staphylococcus aureus bacteremia and osteomyelitis. J Clin Microbiol 2006, 44:595-597.
26. Sakoulas G., Alder J., Thauvin-Eliopoulos C., Moellering R.C., Eliopoulos G.M. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother 2006, 50:1581-1585.
27. Cui L., Tominaga E., Neoh H.M., Hiramatsu K. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2006, 50:1079-1082.
28. Huang Y.T., Hsiao C.H., Liao C.H., Lee C.W., Hsueh P.R. Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan. J Clin Microbiol 2008, 46:1132-1136.
29. Kuo C.C., Wu V., Tsai C.W., Chou N.K., Wang S.S., Hsueh P.R. Fatal bacteremic mycotic aneurysm complicated by acute renal failure caused by Daptomycin-nonsusceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008, 47:859-860.
30. Kuo C.C., Wu V.C., Huang Y.T., Liao C.H., Hsueh P.R. Fatal bacteraemia caused by daptomycin-non-susceptible, vancomycin-intermediate, methicillin-resistant Staphylococcus aureus in a patient with chronic kidney disease. Int J Antimicrob Agents 2009, 33:96-98.
31. Liu C.Y., Wang J.L., Huang Y.T., Hsueh P.R. Development of multiple lung abscesses during daptomycin treatment for right-sided endocarditis caused by methicillin-resistant Staphylococcus aureus. Int J Antimicrob Agents 2008, 32:544-545.
32. Tenover F.C., Moellering R.C. The rationale for revising the clinical and laboratory standards institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 2007, 44:1208-1215.
33. Wootton M., MacGowan A.P., Walsh T.R. Comparative bactericidal activities of daptomycin and vancomycin against glycopeptide-intermediate Staphylococcus aureus (GISA) isolates. Antimicrob Agents Chemother 2006, 50:4195-4197.
34. Sader H.S., Jones R.N. The activity of daptomycin against wild-type Staphylococcus aureus and strains with reduced susceptibility to vancomycin. Clin Infect Dis 2006, 43:798-799.
35. Sader H.S., Fritsche T.R., Jones R.N. Antimicrobial activity of daptomycin tested against clinical strains of indicated species isolated in North American medical centers (2003). Diagn Microbiol Infect Dis 2005, 53:329-332.
36. Pfaller M.A., Sader H.S., Jones R.N. Evaluation of the invitro activity of daptomycin against 19615 clinical isolates of Gram-positive cocci collected in North American hospitals (2002-2005). Diagn Microbiol Infect Dis 2007, 57:459-465.